You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Verisite reset its 2027 Decipher outlook to 12 to 15 amid normalized guideline effects, fewer low-risk diagnoses and digital pathology competition. Q3 produced 27% adjusted EBITDA, over $40 million of cash and a $100 million buyback.
Veracyte reported third-quarter revenue growth of 15% and net income growth of 65%, as testing revenue rose 15% on 13% volume growth, improved average selling price and prior-period collections.
Veracyte reported third-quarter revenue of $151.8 million, up 15% year-over-year, and narrowed 2026 revenue guidance to $590 million to $593 million. Decipher volume growth expectations reset to 12,000 to 15,000 tests, while the board authorized a $100 million repurchase program.
Veracyte reported third-quarter revenue of $151.8 million, up 15%, GAAP net income of $31.5 million and adjusted EBITDA of $41.2 million for the period ended September 30, 2026. It launched a $100 million share repurchase program and expects 2026 revenue of $590 million to $593 million.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Veracyte delivered Q2 revenue of $150.3M (+15% YoY) with adjusted EBITDA margin of 29.2%, launched Prosigna LDT and TrueMRD for MIBC, and raised full-year revenue guidance to $590–$596M (14–15% growth), though it trimmed Decipher volume expectations by ~1,000 tests in the low-risk setting due to NCCN guideline changes.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Depreciation and amortization expense | $4.84M | the three months ended June 30, 2026 filing | — |
| Diagnostic tests reported | 48,389 | the three months ended June 30, 2026 filing | — |
| Product tests sold | 2,578 | the three months ended June 30, 2026 filing | — |
| Stock-based compensation expense | $14.09M | the three months ended June 30, 2026 filing | — |
| Total test volume | 50,967 | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | 86.76M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA as a % of Revenue non-GAAP | 30% | Six Months Ended June 30, 2026 | — |
| Afirma volume | 18,600 | Q2 2026 | — |
| Decipher volume | 29,700 | Q2 2026 | — |
| Diluted earnings per share, non-GAAP non-GAAP | $1.06 | Six Months Ended June 30, 2026 | — |
| Diluted, non-GAAP non-GAAP | 81,753,292 | Six Months Ended June 30, 2026 | — |
| Non-GAAP Gross Margin non-GAAP | 75.3% | Six Months Ended June 30, 2026 | — |
| Non-GAAP Net Income non-GAAP | 86.44M | Six Months Ended June 30, 2026 | — |
| Testing volume | 48,389 | Q2 2026 | — |
| Total volume | 50,967 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCYT
this stock
Veracyte, Inc.
|
$1.96B | -42.2% | +16.0% | 15.8 | 11.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Verisite reset its 2027 Decipher outlook to 12 to 15 amid normalized guideline effects, fewer low-risk diagnoses and digital pathology competition. Q3 produced 27% adjusted EBITDA, over $40 million of cash and a $100 million buyback.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCYT | +0.7% | -43.6% | -45.0% | -51.4% | -42.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.9% | -42.4% | -45.5% | -51.2% | -52.8% |
